13:29 , Dec 5, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived placenta-like organoids could be used to study preeclampsia and other pregnancy-related disorders and screen therapies to treat them. The organoids are generated by culturing human placenta-derived trophoblasts in culture media with...
18:33 , Nov 30, 2018 |  BC Week In Review  |  Company News

Sinovant gains Chinese rights to Angion's BB3

Angion Biomedica Corp. (Uniondale, N.Y.) granted Sinovant Sciences Ltd. (Beijing, China) exclusive rights to develop, commercialize and manufacture BB3 in China, including Hong Kong and Macau, and Taiwan. Angion will receive an upfront payment and...
17:30 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Molecular Partners reports Phase II data for MP0250 in MM

Molecular Partners AG (SIX:MOLN) reported data from seven evaluable patients with relapsed and refractory multiple myeloma (MM) in a Phase II trial showing that 8 mg/kg IV MP0250 every three weeks in combination with Velcade...
20:18 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in SCCHN

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 12 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who were refractory to cetuximab in a Phase I trial showing that...
20:17 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in AML

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 8 evaluable patients with relapsed or refractory acute myelogenous leukemia (AML) in a Phase I trial showing that IV ficlatuzumab (AV-299) plus high-dose IV cytarabine led to 4...
19:16 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Molecular Partners starts Phase II of MP0250 in MM

Molecular Partners AG (SIX:MOLN) began an open-label, European Phase II trial to evaluate MP0250 in combination with Velcade bortezomib plus dexamethasone in about 40 patients with refractory and relapsed multiple myeloma (MM). Patients will receive...
20:16 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

BB3: Ph II GUARD started

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of cardiopulmonary...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
00:53 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of the HGF/SF / c-MET / Src and SHH / IGF-1 / IGF1R pathways could help treat pancreatic ductal adenocarcinoma (PDAC). In human PDAC...
19:55 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

MP0250: Additional Ph I data

Additional data from an open-label, dose-escalation, European Phase I trial in 24 patients with advanced or metastatic solid tumors showed that 0.5-12 mg/kg IV MP0250 every 2 weeks led to significant tumor volume reductions in...